3-piperidinylisochroman-5-ols as dopamine agonists

US7919508B2 · kind B2 · utility

Assignee

• Aventis Pharmaceuticals Inc. · US

Inventors

• Gregory M. Shutske · Somerville, US
• Keith HARRIS · Mount Olive, US
• Kenneth J. Bordeau · Myerstown, US
• Michael R. Angelastro · Mason, US
• Stanly John · Bound Brook, US
• Joseph T. Klein · Bound Brook, US
• Jinqi Lu · Green Brook, US
• Catherine Bomont · Scotch Plains, US

Key dates

• Filing date: Oct 24, 2006
• Grant date: Apr 5, 2011
• Expiry date: Sep 14, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of formula I:a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.